Study identifier:D2452L00006
ClinicalTrials.gov identifier:NCT00242346
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand®) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria
Proteinuria
Phase 3
No
candesartan cilexetil
All
270
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jun 2025 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
Location
Location
Calgary, AB, Canada
Location
Courtice, ON, Canada
Location
Edmonton, AB, Canada
Location
Greenfield Park, QC, Canada
Location
Halifax, NS, Canada
Location
Kelowna, BC, Canada
Location
Kitchener, ON, Canada
Location
Laval, QC, Canada
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.